TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16110020

Group type: EXPERIMENTAL
Intervention: Interval secondary cytoreduction
Number of subjects: 0

Group type: COMPARATOR
Intervention: No interval secondary cytoreduction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (with and without interval secondary cytoreduction)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline FACT-O score
Number of subjects: 0
Study: 11932561

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (GH) treatment, 0.11-0.14 IU.kg-1, daily, s.c.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (GH) treatment
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control period (standard therapy)
Number of subjects: 10
Study: 9806655

Group type: EXPERIMENTAL
Intervention: High grade squamous intraepithelial lesions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Invasive carcinoma
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low grade squamous intraepithelial lesions
Number of subjects: 0
Study: 7632064

Group type: EXPERIMENTAL
Intervention: Terbinafine (250 mg/d)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Griseofulvin (1000 mg/d)
Number of subjects: 195
Study: 2695448

Group type: EXPERIMENTAL
Intervention: 1-week interval schedule of endoscopic injection sclerotherapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: 2-week interval schedule of endoscopic injection sclerotherapy
Number of subjects: 40
Study: 30689860

Group type: EXPERIMENTAL
Intervention: Advanced self‐management patient education programme
Number of subjects: 583

Group type: COMPARATOR
Intervention: Usual care education
Number of subjects: 583
Study: 29092885

Group type: EXPERIMENTAL
Intervention: Iron supplementation (42 mg elemental Fe/d)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Aerobic training (five 25‐min sessions/wk at 75‐85% of maximum heart rate)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Iron supplementation with aerobic training
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo with aerobic training
Number of subjects: 72
Study: 27488411

Group type: EXPERIMENTAL
Intervention: Smartphone app-based intervention (Cool Runnings)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gamification methods within the app
Number of subjects: 0
Study: 24768657

Group type: EXPERIMENTAL
Intervention: Full intervention group (FIG) - GPs not in Catalonia, received all interventions including workshops on rapid tests.
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Partial intervention group (PIG) - Catalan doctors, received all interventions except for the workshop on rapid tests.
Number of subjects: 281
Study: 22107037

Group type: EXPERIMENTAL
Intervention: High person-centered messages
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Low person-centered messages
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: No imbedded supportive message
Number of subjects: 179
Study: 19444731

Group type: EXPERIMENTAL
Intervention: Individual outpatient alcoholism treatment
Number of subjects: 102

Group type: COMPARATOR
Intervention: Couples outpatient alcoholism treatment
Number of subjects: 102
Study: 17327253

Group type: EXPERIMENTAL
Intervention: Counter-flow-type humidifier
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional heated humidifier
Number of subjects: 12

Group type: COMPARATOR
Intervention: Passive heat and moisture exchanger (HME)
Number of subjects: 12
Study: 15206990

Group type: EXPERIMENTAL
Intervention: levocetirizine 5 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 15
Study: 12364460

Group type: EXPERIMENTAL
Intervention: GH 1 micro g/kg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: GH 3 micro g/kg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: GH 6 micro g/kg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 9481346

Group type: EXPERIMENTAL
Intervention: LSU pamphlet
Number of subjects: 610

Group type: COMPARATOR
Intervention: CDC pamphlet
Number of subjects: 610
Study: 8021626

Group type: EXPERIMENTAL
Intervention: Bright colors (e.g., pink, blue, red)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dark colors (e.g., brown, black, gray)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Gender
Number of subjects: 60
Study: 2688780

Group type: EXPERIMENTAL
Intervention: Prescriptive treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Exploratory treatment
Number of subjects: 0
Study: 980598

Group type: EXPERIMENTAL
Intervention: Low-saturated-fat, low-cholesterol (LSFLC) diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 31146039

Group type: EXPERIMENTAL
Intervention: Subthalamic nucleus (STN) deep brain stimulation (DBS)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Globus pallidus internus (GPi) deep brain stimulation (DBS)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Combined factors of disease duration and stimulation type
Number of subjects: 42
Study: 26518352

Group type: EXPERIMENTAL
Intervention: Electric fan therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (routine treatment)
Number of subjects: 30
Study: 25724154

Group type: EXPERIMENTAL
Intervention: ALO‐02 with 20 % ethanol
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: ALO‐02 with 40 % ethanol
Number of subjects: 18

Group type: COMPARATOR
Intervention: ALO‐02 with water
Number of subjects: 18
Study: 23941470

Group type: EXPERIMENTAL
Intervention: Exercise-based programme (ARNI), 24 hours of one-to-one training by an Exercise Professional, plus at least 2 hours weekly unsupervised exercise, over 12-14 weeks
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Exercise-based programme (ARNI)
Number of subjects: 6
Study: 21675444

Group type: EXPERIMENTAL
Intervention: Silver mesh dressing (Tegaderm Ag Mesh dressing), changed every three days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Silver sulfadiazine cream, changed twice a day
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Silver mesh dressing (Tegaderm Ag Mesh dressing)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Silver sulfadiazine cream
Number of subjects: 40
Study: 18608103

Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (5 g/d)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study: 16198215

Group type: EXPERIMENTAL
Intervention: Relational system with relational behaviors
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Identical system with relational behaviors ablated
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control system
Number of subjects: 91
Study: 12401636

Group type: EXPERIMENTAL
Intervention: 0.5 mg of neostigmine plus 3 mg/kg of prilocaine diluted with saline to a total dose of 40 mL
Number of subjects: 30

Group type: COMPARATOR
Intervention: 1 mL of saline plus 3 mg/kg of prilocaine diluted with saline to a total dose of 40 mL
Number of subjects: 30
Study: 9932993

Group type: EXPERIMENTAL
Intervention: Previous argon laser trabeculoplasty
Number of subjects: 498

Group type: COMPARATOR
Intervention: No previous argon laser trabeculoplasty
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Eyes with encapsulated bleb
Number of subjects: 498

Group type: COMPARATOR
Intervention: Eyes without encapsulated bleb
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Both groups after 1 year
Number of subjects: 498
Study: 7778354

Group type: EXPERIMENTAL
Intervention: beta-hydroxyethyl rutosides
Number of subjects: 51

Group type: COMPARATOR
Intervention: physical therapy (cold foot-baths)
Number of subjects: 51

Group type: COMPARATOR
Intervention: control group (only examination)
Number of subjects: 51
Study: 2320648

Group type: EXPERIMENTAL
Intervention: ketocyclazocine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: morphine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: cyclazocine
Number of subjects: 10

Group type: COMPARATOR
Intervention: naloxone
Number of subjects: 10

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study: 647213

Group type: EXPERIMENTAL
Intervention: Low-dose insulin infusion (2.6 U/h)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: High-dose insulin infusion (10.6 U/h)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Both insulin infusions (low and high dose)
Number of subjects: 6
Study: 29462095

Group type: EXPERIMENTAL
Intervention: Topical testosterone applied 3 times a week for 12 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Topical estrogen applied 3 times a week for 12 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo applied 3 times a week for 12 weeks
Number of subjects: 60
Study: 27516420

Group type: COMPARATOR
Intervention: PDT (Photodynamic Therapy)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: PDL-PDT (Pulsed Dye Laser-mediated Photodynamic Therapy)
Number of subjects: 15
Study: 24738516

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone and testosterone enanthate injections
Number of subjects: 14

Group type: COMPARATOR
Intervention: Physical activity programme
Number of subjects: 14
Study: 24107856

Group type: EXPERIMENTAL
Intervention: HEALTHY nutrition intervention
Number of subjects: 0
Study: 20097333

Group type: EXPERIMENTAL
Intervention: Spontaneous LH group
Number of subjects: 124

Group type: COMPARATOR
Intervention: hCG group
Number of subjects: 124
Study: 18422205

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-term anti-platelet therapy
Number of subjects: 0
Study: 16316859

Group type: EXPERIMENTAL
Intervention: Dozozin‐2 (test formulation)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Cardura (reference formulation)
Number of subjects: 24
Study: 12752522

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A) reconstituted over 6 consecutive weeks, injected after reconstitution.
Number of subjects: 85
Study: 11128850

Group type: EXPERIMENTAL
Intervention: CHO treatment (glucose 60 g x L(‐1))
Number of subjects: 15

Group type: COMPARATOR
Intervention: PLA treatment (placebo drink)
Number of subjects: 15

Group type: COMPARATOR
Intervention: RFI treatment (restricted fluid intake with 200 mL placebo)
Number of subjects: 15
Study: 9263617

Group type: EXPERIMENTAL
Intervention: G30 + 100 (training with five repetitions at 30% maximum strength and five isometric contractions at 100% Fmax)
Number of subjects: 12

Group type: COMPARATOR
Intervention: G30 + 0 (training with five repetitions at 30% maximum strength and five contractions with no load)
Number of subjects: 12
Study: 8477114

Group type: EXPERIMENTAL
Intervention: PenFill
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: PenSet
Number of subjects: 14

Group type: COMPARATOR
Intervention: Both formulations
Number of subjects: 14
Study: 3698655

Group type: EXPERIMENTAL
Intervention: 600 mg naftidrofuryl daily
Number of subjects: 61

Group type: COMPARATOR
Intervention: Identical placebo
Number of subjects: 61
Study: 29801123

Group type: EXPERIMENTAL
Intervention: Lampalizumab every 4 weeks (Chroma)
Number of subjects: 1881

Group type: EXPERIMENTAL
Intervention: Lampalizumab every 4 weeks (Spectri)
Number of subjects: 1881

Group type: EXPERIMENTAL
Intervention: Lampalizumab every 6 weeks (Chroma)
Number of subjects: 1881

Group type: EXPERIMENTAL
Intervention: Lampalizumab every 6 weeks (Spectri)
Number of subjects: 1881

Group type: COMPARATOR
Intervention: Sham procedure every 4 weeks (pooled)
Number of subjects: 1881

Group type: COMPARATOR
Intervention: Sham procedure every 6 weeks (pooled)
Number of subjects: 1881
Study: 26751236

Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery and intraperitoneal chemotherapy (5-fluorouracil 550 mg/m²/d for 6 days, repeated monthly for 6 months)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Systemic chemotherapy (oxaliplatin and 5-fluorouracil regimen every second week for 6 months)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery and intraperitoneal chemotherapy
Number of subjects: 48

Group type: COMPARATOR
Intervention: Systemic chemotherapy
Number of subjects: 48
Study: 25323203

Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy (NET-1)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Waiting List (WL) followed by NET (WL/NET-2)
Number of subjects: 76
Study: 22661123

Group type: EXPERIMENTAL
Intervention: Adenosine 25 μg/kg/min
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Adenosine 50 μg/kg/min
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Adenosine 100 μg/kg/min
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Adenosine 200 μg/kg/min
Number of subjects: 166

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166
Study: 20013816

Group type: EXPERIMENTAL
Intervention: SheaFlex70
Number of subjects: 89
Study: 18613854

Group type: EXPERIMENTAL
Intervention: Epoetin beta with concomitant IV iron
Number of subjects: 0

Group type: COMPARATOR
Intervention: Epoetin beta without IV iron
Number of subjects: 0
Study: 16082013

Group type: EXPERIMENTAL
Intervention: Dive rolls
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Back-handsprings
Number of subjects: 14
Study: 12075944

Group type: EXPERIMENTAL
Intervention: Granisetron 3 mg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ramosetron 0.3 mg
Number of subjects: 80
Study: 10621537

Group type: EXPERIMENTAL
Intervention: Nonsteroidal anti-inflammatory drugs for inflamed pterygia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgery for pterygium
Number of subjects: 0
Study: 9295497

Group type: EXPERIMENTAL
Intervention: Food intake during intestinal preparation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fasting during intestinal preparation
Number of subjects: 60
Study: 1496965

Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Captopril (25 mg)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (no medication)
Number of subjects: 13
Study: 6741665

Group type: EXPERIMENTAL
Intervention: Master Questionnaire (MQ)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Energy Balance Knowledge and Cognitive Factors subscales
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Five new subscales developed from cluster and factor analyses
Number of subjects: 0
Study: 31215460

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (intravenous continuous infusion of regular human insulin at a rate of 0.1 units/kg·h to 0.3 units/kg·h)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Plasmapheresis (standard-volume plasmapheresis)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 220

Group type: COMPARATOR
Intervention: Plasmapheresis
Number of subjects: 220
Study: 28902683

Group type: EXPERIMENTAL
Intervention: EOV determination through blinded review by six individuals
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: EOV determination using ventilation dispersion index (VDI)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Prevalence rates of positive and indeterminate EOVs with 10‐s discrete averages
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Prevalence rates of positive and indeterminate EOVs with 30‐s rolling averages
Number of subjects: 243
Study: 27530359

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: C-MAC with D-Blade
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: A.P. Advance with difficult airway blade
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Airtraq with wireless video-viewer
Number of subjects: 0
Study: 23911102

Group type: EXPERIMENTAL
Intervention: Topical application of injectable form of tranexamic acid (500 mg in 5 mL)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Anterior nasal packing with pledgets coated with tetracycline ointment
Number of subjects: 216
Study: 21596621

Group type: EXPERIMENTAL
Intervention: Preoperative short-term radiotherapy (5 × 5 Gy) combined with total mesorectal excision (TME)
Number of subjects: 1861

Group type: COMPARATOR
Intervention: Total mesorectal excision (TME) alone
Number of subjects: 1861

Group type: EXPERIMENTAL
Intervention: Preoperative short-term radiotherapy (5 × 5 Gy) combined with TME
Number of subjects: 1861
Study: 19356743

Group type: EXPERIMENTAL
Intervention: Telemedicine cognitive behavioral therapy (CBT)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Face-to-face cognitive behavioral therapy (CBT)
Number of subjects: 128
Study: 16910866

Group type: EXPERIMENTAL
Intervention: 0.4% ketorolac tromethamine ophthalmic solution
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.5% ketorolac tromethamine ophthalmic solution
Number of subjects: 40
Study: 14962400

Group type: EXPERIMENTAL
Intervention: Key-pressing actions producing auditory effects; no specific dosage or duration mentioned
Number of subjects: 0
Study: 12061017

Group type: EXPERIMENTAL
Intervention: High-strength glass ionomer/resin composite restoration technique
Number of subjects: 0

Group type: COMPARATOR
Intervention: Two occlusal resin composite restoration techniques
Number of subjects: 0
Study: 9232045

Group type: EXPERIMENTAL
Intervention: Intravenous penicillin G sodium, 250,000 U/kg every 24 hours
Number of subjects: 42
Study: 8355866

Group type: EXPERIMENTAL
Intervention: Oral droperidol
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Oral diazepam plus droperidol
Number of subjects: 75

Group type: COMPARATOR
Intervention: Oral diazepam
Number of subjects: 75
Study: 3311134

Group type: EXPERIMENTAL
Intervention: Artificial insemination with husband's semen (high AIH)
Number of subjects: 46

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 46
Study: 29167877

Group type: EXPERIMENTAL
Intervention: Ketamine (0.23 mg/kg infusion over 1 minute followed by 0.58 mg/kg/h infusion over 30 minutes and then 0.29 mg/kg/h infusion over 29 minutes)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 27608437

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: BRV 50mg/day
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: BRV 100mg/day
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: BRV 200mg/day
Number of subjects: 409
Study: 24366670

Group type: EXPERIMENTAL
Intervention: Cetylpyridinium chloride 0.05 % (CPC; Cepacol™)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0.12 % (CHX; Periogard™)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Sterile tap water (Control)
Number of subjects: 52
Study: 23845104

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy for insomnia (CBT-I)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 60
Study: 20103540

Group type: EXPERIMENTAL
Intervention: Celiac plexus block with 25 mL bupivacaine 0.25%
Number of subjects: 19

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 19
Study: 18928102

Group type: EXPERIMENTAL
Intervention: Paidu Baoshen Pill (PBP) 3 g twice a day
Number of subjects: 283

Group type: COMPARATOR
Intervention: Oxidative amylase aldehyde enveloped capsule 5-10 capsules thrice a day
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Paidu Baoshen Pill (PBP)
Number of subjects: 283
Study: 21344828

Group type: EXPERIMENTAL
Intervention: Fluorshield (Dentsply) sealant
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study: 16386522

Group type: EXPERIMENTAL
Intervention: Basiliximab (20 mg/day) on days 0 and 4 posttransplant
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Daclizumab (1 mg/kg per day) on days 0 and 15 posttransplant
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Posttransplant dialysis
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA) introduction
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Tacrolimus introduction
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Kidney graft loss
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Patient survival
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Functioning grafts
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Interleukin-2-receptor blockade
Number of subjects: 49
Study: 12217279

Group type: EXPERIMENTAL
Intervention: Closure with application of fibrin glue (group B)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Standard closure (group A)
Number of subjects: 224
Study: 9930597

Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccine (24% PT-IgE at 7 months)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Whole-cell pertussis vaccine (3% PT-IgE at 7 months)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Atopic children (36% PT-IgE after vaccination)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Children with pertussis (30% PT-IgE)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Nonatopic children (10% PT-IgE after vaccination)
Number of subjects: 189
Study: 8049448

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (1 mg/kg IV for days 1-22, then 0.5 mg/kg for days 22-35)
Number of subjects: 147

Group type: COMPARATOR
Intervention: No methylprednisolone (control group)
Number of subjects: 147
Study: 3133251

Group type: EXPERIMENTAL
Intervention: Purified follicle-stimulating hormone (pure-FSH)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Human menopausal gonadotropin (hMG)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 20
Study: 11604193

Group type: EXPERIMENTAL
Intervention: Danazol 200 mg vaginal suppositories three times during 2 days before administering misoprostol.
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo suppositories.
Number of subjects: 52
Study: 31907080

Group type: EXPERIMENTAL
Intervention: 10 mg daily lutein supplementation for 12 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 30199515

Group type: EXPERIMENTAL
Intervention: PC gaming platform (12 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Computer mouse (control group)
Number of subjects: 40
Study: 26755665

Group type: EXPERIMENTAL
Intervention: Pharmacist-led telephone consultations (2 consultations, 4-6 weeks apart) plus a written summary and a medicines reminder chart.
Number of subjects: 677

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 677
Study: 24866022

Group type: EXPERIMENTAL
Intervention: Na-selenite treatment (1000-μg/2 hours load, followed by 1000-μg/die)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Na-selenite treatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40